drugset / Trial / NCT01154361
AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a multicenter study recruiting patients with angioedema induced by ACEI. Open-label treatment with subcutaneous Icatibant compared to a historic group of 47 patients with ACE inhibitor induced angioedema which the investigators have been previously treated in the investigators centers with current "standard" therapy (250 mg methylprednisolon and 2 mg clemastine). In cases with fast progression of edema after application the study-drug, a second application with icatibant could be necessary. Rescue medication and intervention.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clemastine | Small molecule | 2 mg | Intravenous |
| Comparator | Cortisone acetate | Other / unclassified | — | Intravenous |
| Subject | Icatibant | Peptide | 30 mg | Subcutaneous |